PacBio (PACB) announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina. PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and granted a non-exclusive license certain intellectual property back to PacBio. The transaction closed on January 30, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Pacific Biosciences: Improving Fundamentals, Emerging Growth Catalysts Support Buy Rating and $3 Target
- Pacific Biosciences: Emerging From a Challenging 2025 With Renewed Growth Momentum and Justifying a Buy Rating
- PacBio Announces Strong Preliminary Q4 and 2025 Revenue
- PacBio announces plans for n-Lorem Foundation collaboration
- PacBio reports preliminary Q4 revenue $44.6M, consensus $41.96M